Michael Walsh

Michael is the founder of Evida Biosciences, a precision medicine company disrupting the $70 billion chronic inflammatory disease market through novel therapeutics, precision clinical testing, and pharma partnerships. Previously, he was a Board Member at Lineagen and held executive roles at Cypress Biosciences and Proprius Pharmaceuticals, which he founded and led to its acquisition. He also co-founded Prometheus Laboratories and held leadership roles at Quidel Corporation and La Jolla Pharmaceuticals.